Exploiting Polypharmacology in Precision Oncology: Identification of Differential Kinase Off-targets Among Clinical PARP Inhibitors
Poster Nov 08, 2017
Dr. Albert A. Antolin, Dr. Jordi Mestres, Prof. Paul Workman and Dr. Bissan Al-Lazikani
A more comprehensive and systems-based approach to pharmacology is uncovering that drugs tend to bind to more than one target, a behaviour commonly referred to as polypharmacology with clinical implications that are still not well understood.1
The increasing availability of ligand-target interaction data in the public domain in resources such as canSAR2 enables the development of computational methods to predict polypharmacology, that are becoming a cost-effective means to uncover new targets of drugs. PARP inhibitors are a new class of targeted small-molecule cancer therapeutics that have shown unexplained differential effects in cellular models and clinical trials.3
Can we use computational methods to identify previously unknown off-targets of PARP inhibitors that can explain their observed differences?
(1) Jalencas X, Mestres J. On the origins of drug polypharmacology. Med. Chem. Commun.,4, 80-87 (2013).
(2) Tym JE, Mitsopoulos C, Coker EA, Razaz P, Schierz AC, Antolin AA, Al-Lazikani B. CanSAR: updated cancer research and drug discovery knowledgebase. Nucleic Acids Res. 44, D938-43 (2016).
(3) Antolín AA, Mestres J. Linking off-target kinase pharmacology to the differential cellular effects observed among PARP inhibitors. Oncotarget. 5, 3023-8 (2014).
2nd AI Pharma Innovation: Drug Discovery 2019 Summit
Feb 27 - Feb 28, 2019
5th International Congress on Epigenetics & Chromatin
Aug 22 - Aug 23, 2019
14th World Congress on Medicinal Chemistry and Drug Design
Jun 10 - Jun 11, 2019
International Conference on e-Health and Healthcare Innovations
May 08 - May 09, 2019